Drug Approval | December 27, 2024
Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH